Seborrheic dermatitis is a chronic inflammatory skin disorder characterized by scaly, erythematous, and itchy skin in sebum-rich areas of the body (e.g., scalp, face, upper chest). The severity of disease can range from mild dandruff to widespread patches of red, itchy, inflamed skin lesions, which place a social and psychological burden on patients. Topical antifungals are the entrenched treatment; topical corticosteroids are common second-line options, although safety and tolerability concerns render them suboptimal medications for longer-term symptom management. Novel nonsteroidal therapies, including topical phosphodiesterase-4 inhibitors (i.e., Arcutis Biotherapeutics’ topical roflumilast), are in clinical development. If efficacious, they stand to capitalize on the unmet need for additional effective and safe therapies in this space.
- What are the key unmet needs and opportunities in the seborrheic dermatitis therapy market?
- What is the prevalence of seborrheic dermatitis in the United States?
- How are seborrheic dermatitis patients currently treated in the United States?
- What is the expected impact of new therapies launching for seborrheic dermatitis?
- How does each current and future player influence the market, and how will this scenario change in the future?
- What are the key drivers and limiters of the seborrheic dermatitis therapy market?
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
- Seborrheic Dermatitis - Executive Insights - Executive Insights (US)
- Executive Insights Seborrheic Dermatitis - June 2020
Author(s): Raina Priyadarshini, Ph.D.
Raina Priyadarshini, Ph.D., is a senior analyst on the Infectious, Niche, and Rare Diseases team at DRG, part of Clarivate. Prior to joining DRG, she was an analyst in the biopharmaceutical industry, where she developed novel disease target-drug combinations for rare CNS and hematological disorders. Dr. Priyadarshini trained as a molecular biologist; her research focused on the interplay between tumor suppressor proteins and oncoproteins. She received her doctorate from the National Institute of Immunology.